{"id":2631,"date":"2018-05-08T23:47:37","date_gmt":"2018-05-08T18:17:37","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2631"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"notizia-latest-pharma-news-4","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4","title":{"rendered":"Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&amp;D program<\/strong><\/p>\n<p style=\"text-align: justify;\">Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&amp;D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger was hired by Genentech late in 2011 to supervise HER2 breast cancer programs, later he was promoted to the position of SVP global clinical development for oncology and hematology group.<\/p>\n<p style=\"text-align: justify;\"><strong>Minor effects of multiple genes collectively determine migraine risk<\/strong><\/p>\n<p style=\"text-align: justify;\">A group of scientists studied data of more than 1,500\u00a0families in Finland to examine two conflicting theories about how migraines run in families. In the study, they discovered that collective effects of many genes\u00a0determine\u00a0migraine risk\u00a0more than that be a few powerful gene.<\/p>\n<p style=\"text-align: justify;\"><strong>After FDA rejection, Celgene all set to refile ozanimod in 2019 Q1<\/strong><\/p>\n<p style=\"text-align: justify;\">Celgene suffered a major setback in February after getting refuse-to-file letter for its multiple sclerosis drug ozanimod. Now, the company is all set and is expecting to\u00a0resubmit\u00a0the NDA in the first quarter of 2019. While 2019 is not a great timeframe, still it\u2019s better than refiling in 2020 and waiting for a long time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&amp;D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&amp;D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger was hired by Genentech late in 2011 to supervise HER2 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1618,776,155,1155,1135,1029,1230,1261,639,1610],"industry":[17225],"therapeutic_areas":[17235,17233,17245,17228],"class_list":["post-2631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atara-biotherapeutics","tag-business-cocktail","tag-celgene","tag-consultancy","tag-genentech","tag-market-report","tag-pharma-consultancy","tag-pharma-consulting","tag-pharma-news","tag-pharmaceutical-industry-news","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Atara Biotherapeutics hires; Minor effects of multiple genes determine risk<\/title>\n<meta name=\"description\" content=\"Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&amp;D global head. During the time in Genentech, Berger was involved in the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atara Biotherapeutics hires; Minor effects of multiple genes determine risk\" \/>\n<meta property=\"og:description\" content=\"Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&amp;D global head. During the time in Genentech, Berger was involved in the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-08T18:17:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Atara Biotherapeutics hires; Minor effects of multiple genes determine risk","description":"Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4","og_locale":"en_US","og_type":"article","og_title":"Atara Biotherapeutics hires; Minor effects of multiple genes determine risk","og_description":"Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-08T18:17:37+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4","name":"Atara Biotherapeutics hires; Minor effects of multiple genes determine risk","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-05-08T18:17:37+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-4#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">atara biotherapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">market report<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical industry news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">atara biotherapeutics<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">market report<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical industry news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 8, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 8, 2018 11:47 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2631"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2631\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2631"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2631"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}